ClinicalTrials.gg
CompletedNCT04179474Updated Mar 10, 2021Results posted

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

A Phase 1 interventional study of Ubrogepant and Erenumab in Migraine, sponsored by Allergan. Completed at 2 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.

Enrollment
12th of 14
40 · median 507
Started
2019
the only one that year
Phase 1
2 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
6 of 14
Allergan

Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1, and was the 6th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About ubrogepant

ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ubrogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • ubrogepant
  • erenumab
  • galcanezumab
  • safety
  • tolerability
  • interaction
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, (ICHD-3, 2018)
  • By history, the participant's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
  • History of at least 2 migraine attacks per month in the 2 months prior to Screening
  • Have a sitting pulse rate ≥ 45 beats per minute (bpm) and ≤ 100 bpm during the vital sign assessment at the Screening Visit. Clinical site may perform a maximum of 2 repeats of vital sign measurements if the initial measurement is out of range.
  • Negative test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, cannabinoids, opiates, and phencyclidine at the Screening Visit and Day -1; unless explained by concomitant medication use (eg, opioids prescribed for migraine pain)
  • Participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period

Exclusion criteria

Exclusion Criteria:

  • Difficulty distinguishing migraine headache from tension-type or other headaches
  • Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3
  • Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3
  • Required hospital treatment of a migraine attack 3 or more times in the 6 months prior to Screening
  • Has a chronic non-headache pain condition requiring daily pain medication (with the exception of pregabalin)
  • Has cardiovascular or cerebrovascular disease per the investigator's opinion
  • Previously participated in an study of ubrogepant
  • Participation in any other clinical investigation using an experimental drug within 30 days prior to study intervention administration
  • Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to study intervention administration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Part 1 (Intervention A then B then D)

    Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention B: Single subcutaneous (SC) injection of erenumab 140 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.

    Drug: Ubrogepant · Drug: Erenumab

  • Experimental
    Part 2 (Intervention A then C then D)

    Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention C: Two SC injections of galcanezumab 120 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.

    Drug: Ubrogepant · Drug: Galcanezumab

Interventions

  • Oral administration of 100 mg ubrogepant tablet once daily \[Intervention A=single dose and Intervention D=repeated daily dose\].

  • Single dose subcutaneous (SC) injection of erenumab 140 mg \[Intervention B\].

  • 2 SC injections of galcanezumab 120 mg \[Intervention C\].

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  2. Part 2: AUC0-t for Ubrogepant Alone and in Combination With Galcanezumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  3. Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) for Ubrogepant Alone and in Combination With Erenumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  4. Part 2: AUC0-∞ for Ubrogepant Alone and in Combination With Galcanezumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  5. Part 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  6. Part 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

Secondary outcomes

  1. Part 1: Time of Maximum Plasma Drug Concentration (Tmax) for Ubrogepant Alone and in Combination With Erenumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  2. Part 2: Tmax for Ubrogepant Alone and in Combination With Galcanezumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  3. Part 1: Terminal Elimination Rate Constant (λz) for Ubrogepant Alone and in Combination With Erenumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  4. Part 2: λz for Ubrogepant Alone and in Combination With Galcanezumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  5. Part 1: Terminal Elimination Half-life (T½) for Ubrogepant Alone and in Combination With Erenumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  6. Part 2: T½ for Ubrogepant Alone and in Combination With Galcanezumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  7. Part 1: Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for Ubrogepant Alone and in Combination With Erenumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  8. Part 2: CL/F for Ubrogepant Alone and in Combination With Galcanezumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  9. Part 1: Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Ubrogepant Alone in Combination With Erenumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  10. Part 2: Vz/F for Ubrogepant Alone in Combination With Galcanezumab

    Time frame: Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose

  11. Number of Participants Who Had Potentially Clinically Significant (PCS) Postbaseline Vital Sign Values

    Vital Signs included assessments of Blood Pressure, Pulse Rate, Weight, Respiratory Rate and Temperature. The investigator determined if the postbaseline Vital Sign values were potentially clinically significant using the Vital Sign PCS Criteria in the Statistical Analysis Plan (SAP).

    Time frame: End of Dosing (EOD): Within 7 days of Day 16 or at the time of early termination (Up to Day 16)

  12. Number of Participants Who Had PCS Postbaseline Laboratory Values

    Laboratory assessments included Chemistry, Hematology and Urinalysis tests. The investigator determined if the postbaseline laboratory results were potentially clinically significant using the Clinical Laboratory PCS Criteria in the SAP. Assessments of Chemistry only were collected at the Final Follow-up Visit

    Time frame: EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16); Follow-up Visit 30 days after last dose (Up to Day 45 +/-3 days)

  13. Number of Participants Who Had PCS Postbaseline Physical Examination Values

    Time frame: EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16)

  14. Number of Participants Who Had PCS Postbaseline Electrocardiogram (ECG) Values

    A standard 12-lead ECG was performed. The investigator determined if the ECG postbaseline values were potentially clinically significant using the ECG PCS Criteria in the SAP.

    Time frame: EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16)

  15. Number of Participants With Adverse Events (AEs) by Severity, Related AEs and AEs Leading to Discontinuation

    An AE is any untoward medical occurrence in a patient or a participant using an investigational drug, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The investigator determined if the AE was causally related to treatment. The investigator determined if the severity of the AE was Mild (transient with minimal intervention that does not interfere with usual activities), Moderate ( usually alleviated with an intervention, interferes with usual activities causing discomfort but does not cause permanent harm) or Severe (interrupts usual activities, affects clinical status or requires intensive intervention).

    Time frame: First dose to within 30 days after last dose (Up to Day 45 +/-3 days)

07

Results

Posted Mar 10, 2021

Participant flow

Treatment Period 1 (First Intervention)
Participant flow — Treatment Period 1 (First Intervention)
MilestonePart 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)
Started2020
Completed2020
Not completed00
Treatment Period 2 (Second Intervention)
Participant flow — Treatment Period 2 (Second Intervention)
MilestonePart 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)
Started1920
Completed1920
Not completed00
Treatment Period 3 (Third Intervention)
Participant flow — Treatment Period 3 (Third Intervention)
MilestonePart 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)
Started1919
Completed1919
Not completed00

Outcome measures

PrimaryPart 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · nanogram*hour/milliliter (ng*h/mL)
Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab
nanogram*hour/milliliter (ng*h/mL)Part 1: Ubrogepant AlonePart 1: Ubrogepant in Combination With Erenumab
Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Time t (AUC0-t) for Ubrogepant Alone and in Combination With Erenumab1841.42 ± 490.171959.96 ± 639.51
Statistical analysis
  • Part 1: Ubrogepant Alone vs Part 1: Ubrogepant in Combination With Erenumab · Ratio of geometric mean percentage: 105.55 · 90% CI 96.21 to 115.79Ratio of Geometric Mean Percentage=Ubrogepant in Combination with Erenumab/Ubrogepant Alone \* 100
PrimaryPart 2: AUC0-t for Ubrogepant Alone and in Combination With Galcanezumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · ng*h/mL
Part 2: AUC0-t for Ubrogepant Alone and in Combination With Galcanezumab
ng*h/mLPart 2: Ubrogepant AlonePart 2: Ubrogepant in Combination With Galcanezumab
Part 2: AUC0-t for Ubrogepant Alone and in Combination With Galcanezumab1700.31 ± 913.421758.05 ± 1033.44
Statistical analysis
  • Part 2: Ubrogepant Alone vs Part 2: Ubrogepant in Combination With Galcanezumab · Ratio of geometric mean percentage: 105.03 · 90% CI 89.55 to 123.19Ratio of Geometric Mean Percentage=Ubrogepant in Combination with Galcanezumab/Ubrogepant Alone \* 100
PrimaryPart 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) for Ubrogepant Alone and in Combination With Erenumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · ng*h/mL
Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) for Ubrogepant Alone and in Combination With Erenumab
ng*h/mLPart 1: Ubrogepant AlonePart 1: Ubrogepant in Combination With Erenumab
Part 1: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC0-∞) for Ubrogepant Alone and in Combination With Erenumab1878.25 ± 497.821993.40 ± 639.22
Statistical analysis
  • Part 1: Ubrogepant Alone vs Part 1: Ubrogepant in Combination With Erenumab · Ratio of geometric mean percentage: 105.38 · 90% CI 96.19 to 115.45Ratio of Geometric Mean Percentage=Ubrogepant in Combination with Erenumab/Ubrogepant Alone \* 100
PrimaryPart 2: AUC0-∞ for Ubrogepant Alone and in Combination With Galcanezumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · ng*h/mL
Part 2: AUC0-∞ for Ubrogepant Alone and in Combination With Galcanezumab
ng*h/mLPart 2: Ubrogepant AlonePart 2: Ubrogepant in Combination With Galcanezumab
Part 2: AUC0-∞ for Ubrogepant Alone and in Combination With Galcanezumab1732.22 ± 928.061793.74 ± 1057.02
Statistical analysis
  • Part 2: Ubrogepant Alone vs Part 2: Ubrogepant in Combination With Galcanezumab · Ratio of geometric mean percentage: 104.76 · 90% CI 89.68 to 122.38Ratio of Geometric Mean Percentage=Ubrogepant in Combination with Galcanezumab/Ubrogepant Alone \* 100
PrimaryPart 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · ng/mL
Part 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab
ng/mLPart 1: Ubrogepant AlonePart 1: Ubrogepant in Combination With Erenumab
Part 1: Maximum Plasma Drug Concentration (Cmax) for Ubrogepant Alone in Combination With Erenumab459.32 ± 168.56486.80 ± 201.52
Statistical analysis
  • Part 1: Ubrogepant Alone vs Part 1: Ubrogepant in Combination With Erenumab · Ratio of geometric mean percentage: 103.86 · 90% CI 93.01 to 115.98Ratio of Geometric Mean Percentage=Ubrogepant in Combination with Erenumab/Ubrogepant Alone \* 100
PrimaryPart 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · ng/mL
Part 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab
ng/mLPart 2: Ubrogepant AlonePart 2: Ubrogepant in Combination With Galcanezumab
Part 2: Cmax for Ubrogepant Alone and in Combination With Galcanezumab415.34 ± 225.64375.12 ± 152.08
Statistical analysis
  • Part 2: Ubrogepant Alone vs Part 2: Ubrogepant in Combination With Galcanezumab · Ratio of geometric mean percentage: 99.55 · 90% CI 82.27 to 120.45Ratio of Geometric Mean Percentage=Ubrogepant in Combination with Galcanezumab/Ubrogepant Alone \* 100
SecondaryPart 1: Time of Maximum Plasma Drug Concentration (Tmax) for Ubrogepant Alone and in Combination With Erenumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Median · hour
Part 1: Time of Maximum Plasma Drug Concentration (Tmax) for Ubrogepant Alone and in Combination With Erenumab
hourPart 1: Ubrogepant AlonePart 1: Ubrogepant in Combination With Erenumab
Part 1: Time of Maximum Plasma Drug Concentration (Tmax) for Ubrogepant Alone and in Combination With Erenumab1.50 (1.00 to 3.00)1.48 (0.50 to 3.02)
SecondaryPart 2: Tmax for Ubrogepant Alone and in Combination With Galcanezumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Median · hour
Part 2: Tmax for Ubrogepant Alone and in Combination With Galcanezumab
hourPart 2: Ubrogepant AlonePart 2: Ubrogepant in Combination With Galcanezumab
Part 2: Tmax for Ubrogepant Alone and in Combination With Galcanezumab1.50 (1.00 to 6.00)1.50 (0.98 to 6.00)
SecondaryPart 1: Terminal Elimination Rate Constant (λz) for Ubrogepant Alone and in Combination With Erenumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · 1/hour
Part 1: Terminal Elimination Rate Constant (λz) for Ubrogepant Alone and in Combination With Erenumab
1/hourPart 1: Ubrogepant AlonePart 1: Ubrogepant in Combination With Erenumab
Part 1: Terminal Elimination Rate Constant (λz) for Ubrogepant Alone and in Combination With Erenumab0.136 ± 0.0250.156 ± 0.034
SecondaryPart 2: λz for Ubrogepant Alone and in Combination With Galcanezumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · 1/hour
Part 2: λz for Ubrogepant Alone and in Combination With Galcanezumab
1/hourPart 2: Ubrogepant AlonePart 2: Ubrogepant in Combination With Galcanezumab
Part 2: λz for Ubrogepant Alone and in Combination With Galcanezumab0.150 ± 0.0530.165 ± 0.056
SecondaryPart 1: Terminal Elimination Half-life (T½) for Ubrogepant Alone and in Combination With Erenumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · hour
Part 1: Terminal Elimination Half-life (T½) for Ubrogepant Alone and in Combination With Erenumab
hourPart 1: Ubrogepant AlonePart 1: Ubrogepant in Combination With Erenumab
Part 1: Terminal Elimination Half-life (T½) for Ubrogepant Alone and in Combination With Erenumab5.26 ± 1.004.62 ± 0.94
SecondaryPart 2: T½ for Ubrogepant Alone and in Combination With Galcanezumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · hour
Part 2: T½ for Ubrogepant Alone and in Combination With Galcanezumab
hourPart 2: Ubrogepant AlonePart 2: Ubrogepant in Combination With Galcanezumab
Part 2: T½ for Ubrogepant Alone and in Combination With Galcanezumab5.04 ± 1.474.60 ± 1.35
SecondaryPart 1: Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for Ubrogepant Alone and in Combination With Erenumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · liter/hour
Part 1: Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for Ubrogepant Alone and in Combination With Erenumab
liter/hourPart 1: Ubrogepant AlonePart 1: Ubrogepant in Combination With Erenumab
Part 1: Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for Ubrogepant Alone and in Combination With Erenumab57.35 ± 17.2054.74 ± 16.27
SecondaryPart 2: CL/F for Ubrogepant Alone and in Combination With Galcanezumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · liter/hour
Part 2: CL/F for Ubrogepant Alone and in Combination With Galcanezumab
liter/hourPart 2: Ubrogepant AlonePart 2: Ubrogepant in Combination With Galcanezumab
Part 2: CL/F for Ubrogepant Alone and in Combination With Galcanezumab72.90 ± 38.0768.94 ± 28.12
SecondaryPart 1: Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Ubrogepant Alone in Combination With Erenumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · liter
Part 1: Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Ubrogepant Alone in Combination With Erenumab
literPart 1: Ubrogepant AlonePart 1: Ubrogepant in Combination With Erenumab
Part 1: Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz/F) for Ubrogepant Alone in Combination With Erenumab436.95 ± 158.11375.84 ± 161.42
SecondaryPart 2: Vz/F for Ubrogepant Alone in Combination With Galcanezumab
Time frame:
Day 1 (Treatment Period 1): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose; Day 12 (Day 1 of Treatment Period 3): Predose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 14, and 24 hours postdose
Reported as:
Mean · liter
Part 2: Vz/F for Ubrogepant Alone in Combination With Galcanezumab
literPart 2: Ubrogepant AlonePart 2: Ubrogepant in Combination With Galcanezumab
Part 2: Vz/F for Ubrogepant Alone in Combination With Galcanezumab568.66 ± 497.92449.26 ± 213.84
SecondaryNumber of Participants Who Had Potentially Clinically Significant (PCS) Postbaseline Vital Sign Values

Vital Signs included assessments of Blood Pressure, Pulse Rate, Weight, Respiratory Rate and Temperature. The investigator determined if the postbaseline Vital Sign values were potentially clinically significant using the Vital Sign PCS Criteria in the Statistical Analysis Plan (SAP).

Time frame:
End of Dosing (EOD): Within 7 days of Day 16 or at the time of early termination (Up to Day 16)
Reported as:
Count of participants · Participants
Number of Participants Who Had Potentially Clinically Significant (PCS) Postbaseline Vital Sign Values
ParticipantsPart 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)
Number of Participants Who Had Potentially Clinically Significant (PCS) Postbaseline Vital Sign Values00
SecondaryNumber of Participants Who Had PCS Postbaseline Laboratory Values

Laboratory assessments included Chemistry, Hematology and Urinalysis tests. The investigator determined if the postbaseline laboratory results were potentially clinically significant using the Clinical Laboratory PCS Criteria in the SAP. Assessments of Chemistry only were collected at the Final Follow-up Visit

Time frame:
EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16); Follow-up Visit 30 days after last dose (Up to Day 45 +/-3 days)
Reported as:
Count of participants · Participants
Number of Participants Who Had PCS Postbaseline Laboratory Values
ParticipantsPart 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)
Hematology; EOD01
Chemistry; EOD00
Chemistry; Follow-up Visit11
Urinalysis; EOD10
SecondaryNumber of Participants Who Had PCS Postbaseline Physical Examination Values
Time frame:
EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16)

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Had PCS Postbaseline Electrocardiogram (ECG) Values

A standard 12-lead ECG was performed. The investigator determined if the ECG postbaseline values were potentially clinically significant using the ECG PCS Criteria in the SAP.

Time frame:
EOD: Within 7 days of Day 16 or at the time of early termination (Up to Day 16)
Reported as:
Count of participants · Participants
Number of Participants Who Had PCS Postbaseline Electrocardiogram (ECG) Values
ParticipantsPart 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)
Number of Participants Who Had PCS Postbaseline Electrocardiogram (ECG) Values00
SecondaryNumber of Participants With Adverse Events (AEs) by Severity, Related AEs and AEs Leading to Discontinuation

An AE is any untoward medical occurrence in a patient or a participant using an investigational drug, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. The investigator determined if the AE was causally related to treatment. The investigator determined if the severity of the AE was Mild (transient with minimal intervention that does not interfere with usual activities), Moderate ( usually alleviated with an intervention, interferes with usual activities causing discomfort but does not cause permanent harm) or Severe (interrupts usual activities, affects clinical status or requires intensive intervention).

Time frame:
First dose to within 30 days after last dose (Up to Day 45 +/-3 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) by Severity, Related AEs and AEs Leading to Discontinuation
ParticipantsPart 1: Intervention A (Ubrogepant)Part 1: Intervention B (Erenumab)Part 1: Intervention D (Ubrogepant)Part 2: Intervention A (Ubrogepant)Part 2: Intervention C (Galcanezumab)Part 2: Intervention D (Ubrogepant)
All AEs787234
AEs by Severity: Mild786234
AEs by Severity: Moderate000000
AEs by Severity: Severe001000
Related AEs275033
AEs Leading to Discontinuation000000

Adverse events

Collected over First dose to within 30 days after last dose (Up to Day 45 +/-3 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Intervention A (Ubrogepant)0/20 (0%)0/20 (0%)7/20 (35%)
Part 1: Intervention B (Erenumab)0/19 (0%)0/19 (0%)8/19 (42.1%)
Part 1: Intervention D (Ubrogepant)0/19 (0%)0/19 (0%)7/19 (36.8%)
Part 2; Intervention A (Ubrogepant)0/20 (0%)0/20 (0%)2/20 (10%)
Part 2: Intervention C (Galcanezumab)0/20 (0%)0/20 (0%)3/20 (15%)
Part 2: Intervention D (Ubrogepant)0/19 (0%)0/19 (0%)4/19 (21.1%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPart 1: Intervention A (Ubrogepant)Part 1: Intervention B (Erenumab)Part 1: Intervention D (Ubrogepant)Part 2; Intervention A (Ubrogepant)Part 2: Intervention C (Galcanezumab)Part 2: Intervention D (Ubrogepant)
HeadacheNervous system disorders2/206/191/190/203/200/19
Puncture site painGeneral disorders3/200/190/192/200/200/19
ConstipationGastrointestinal disorders0/201/192/190/200/200/19
Abdominal pain upperGastrointestinal disorders0/200/192/190/200/201/19
NauseaGastrointestinal disorders0/200/192/190/200/200/19
DizzinessNervous system disorders0/200/191/190/200/202/19
FlatulenceGastrointestinal disorders0/201/190/190/200/200/19
Abdominal painGastrointestinal disorders0/200/191/190/200/200/19
VomitingGastrointestinal disorders0/200/191/191/200/200/19
Musculoskeletal painMusculoskeletal and connective tissue disorders0/201/190/190/200/200/19

Baseline characteristics

Safety population included all participants who received/took at least 1 administration of study intervention in Part 1 or Part 2.

Age, Customized
Age, Customized(years)Part 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)Total
Mean32.2 (20 to 50)38.4 (18 to 50)35.3 (18 to 50)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)Total
Female101222
Male10818
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)Total
Hispanic or Latino044
Not Hispanic or Latino201636
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7916
White121123
More than one race101
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Part 1 (Intervention A Then B Then D)Part 2 (Intervention A Then C Then D)Total
North America202040
08

Study locations

2 sites
  • QPS
    Springfield, Missouri 65802, United States
  • Spaulding
    West Bend, Wisconsin 53095, United States
09

References and documents

Publications

  • Jakate A,Boinpally R, Butler M, Borbridge L, Contreras-De Lama J, McGeeney D, Periclou A. Safety and tolerability of ubrogepant for the acute treatment of migraine following co-administration with preventive monoclonal antibody treatment [abstract]. In:62nd Annual Scientific Meeting American Headache Society; June2020; San Diego, California.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Dec 2019, 2 months.

Results were first posted in Mar 2021, 1 year 2 months after primary completion.

Of 39 industry-sponsored phase 1 interventional studies under Migraine Disorders, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 2 months is below that.

Counting every sponsor, half of 53 studies reached it within 6 months; a quarter within 2 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2019
First posted
Nov 27, 2019
StartActual
Sep 26, 2019
Primary completionActual
Dec 23, 2019
CompletionActual
Dec 23, 2019
Results first posted
Mar 10, 2021
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04179474
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Sep 26, 2019
Primary completion
Dec 23, 2019
Completion
Dec 23, 2019
Results posted
Mar 10, 2021
Last update
Mar 10, 2021

Study contacts

Ramesh Boinpally
study director · Allergan

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ubrogepant · Erenumab · Galcanezumab

Start the discussion